140 related articles for article (PubMed ID: 6774280)
1. Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog.
Neuwelt EA; Frenkel EP; Rapoport S; Barnett P
Neurosurgery; 1980 Jul; 7(1):36-43. PubMed ID: 6774280
[TBL] [Abstract][Full Text] [Related]
2. Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery.
Neuwelt EA; Maravilla KR; Frenkel EP; Rapaport SI; Hill SA; Barnett PA
J Clin Invest; 1979 Aug; 64(2):684-8. PubMed ID: 457877
[TBL] [Abstract][Full Text] [Related]
3. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors.
Neuwelt EA; Hill SA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Lewis SE; Ehle AL; Beyer CW
Cancer Treat Rep; 1981; 65 Suppl 2():39-43. PubMed ID: 6809316
[TBL] [Abstract][Full Text] [Related]
4. Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain.
Neuwelt EA; Barnett PA; McCormick CI; Frenkel EP; Minna JD
Neurosurgery; 1985 Sep; 17(3):419-23. PubMed ID: 3930991
[TBL] [Abstract][Full Text] [Related]
5. Use of enhanced computerized tomography to evaluate osmotic blood-brain barrier disruption.
Neuwelt EA; Maravilla KR; Frenkel EP; Barnett P; Hill S; Moore RJ
Neurosurgery; 1980 Jan; 6(1):49-56. PubMed ID: 6153461
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
7. Enhanced disruption of the blood brain barrier by intracarotid mannitol injection during transient cerebral hypoperfusion in rabbits.
Wang M; Etu J; Joshi S
J Neurosurg Anesthesiol; 2007 Oct; 19(4):249-56. PubMed ID: 17893577
[TBL] [Abstract][Full Text] [Related]
8. Osmotic blood-brain barrier disruption in the posterior fossa of the dog.
Neuwelt EA; Glasberg M; Diehl J; Frenkel EP; Barnett P
J Neurosurg; 1981 Nov; 55(5):742-8. PubMed ID: 6796658
[TBL] [Abstract][Full Text] [Related]
9. Osmotic opening of the blood-brain barrier to methotrexate in the rat.
Ohno K; Fredericks WR; Rapoport SI
Surg Neurol; 1979 Oct; 12(4):323-8. PubMed ID: 524251
[TBL] [Abstract][Full Text] [Related]
10. Intracarotid infusion of hypertonic mannitol changes permeability of blood-brain barrier to methotrexate in rats.
Pan GY; Liu XD; Liu GQ
Acta Pharmacol Sin; 2000 Jul; 21(7):613-6. PubMed ID: 11360668
[TBL] [Abstract][Full Text] [Related]
11. Blood-brain barrier disruption using mannitol: time course and electron microscopy studies.
Cosolo WC; Martinello P; Louis WJ; Christophidis N
Am J Physiol; 1989 Feb; 256(2 Pt 2):R443-7. PubMed ID: 2492773
[TBL] [Abstract][Full Text] [Related]
12. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier.
Neuwelt EA; Barnett PA; Bigner DD; Frenkel EP
Proc Natl Acad Sci U S A; 1982 Jul; 79(14):4420-3. PubMed ID: 6289301
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption.
Neuwelt EA; Diehl JT; Vu LH; Hill SA; Michael AJ; Frenkel EP
Ann Intern Med; 1981 Apr; 94(4 pt 1):449-54. PubMed ID: 6782926
[TBL] [Abstract][Full Text] [Related]
14. The effects of pentobarbital on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats.
Chi OZ; Chun TW; Liu X; Weiss HR
Anesth Analg; 1998 Jun; 86(6):1230-5. PubMed ID: 9620510
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of CNS penetration of methotrexate by hyperosmolar intracarotid mannitol or carcinomatous meningitis.
Hasegawa H; Allen JC; Mehta BM; Shapiro WR; Posner JB
Neurology; 1979 Sep; 29(9 Pt 1):1280-6. PubMed ID: 573408
[TBL] [Abstract][Full Text] [Related]
16. Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain.
Erdlenbruch B; Schinkhof C; Kugler W; Heinemann DE; Herms J; Eibl H; Lakomek M
Br J Pharmacol; 2003 Jun; 139(4):685-94. PubMed ID: 12812991
[TBL] [Abstract][Full Text] [Related]
17. Effects of combination of vasodilator drugs and hypertonic solutions on methotrexate distribution into the rat brain.
Abe H
Jpn J Pharmacol; 1988 Nov; 48(3):373-6. PubMed ID: 3146662
[TBL] [Abstract][Full Text] [Related]
18. Blood-brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats.
Cosolo W; Christophidis N
Cancer Res; 1987 Dec; 47(23):6225-8. PubMed ID: 3119195
[TBL] [Abstract][Full Text] [Related]
19. The effects of magnesium sulfate on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats.
Kaya M; Gulturk S; Elmas I; Kalayci R; Arican N; Kocyildiz ZC; Kucuk M; Yorulmaz H; Sivas A
Life Sci; 2004 Nov; 76(2):201-12. PubMed ID: 15519365
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study.
Shapiro WR; Voorhies RM; Hiesiger EM; Sher PB; Basler GA; Lipschutz LE
Cancer Res; 1988 Feb; 48(3):694-701. PubMed ID: 3335031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
